GND-323

GND-323 is an investigational antineoplastic agent being developed by Gandeeva Therapeutics. It is designed to target and modulate the Mitogen-Activated Protein Kinase (MAPK) signaling pathway, a critical driver of cell growth and survival that is frequently mutated or overexpressed in various cancers. The drug was discovered using Gandeeva's proprietary platform, which combines high-resolution cryo-electron microscopy (cryo-EM) with artificial intelligence and machine learning to visualize and target protein-protein and protein-ligand interactions that were previously considered "undruggable." As of early 2024, GND-323 is in the preclinical stage of development, specifically within discovery and optimization phases, aimed at treating unspecified oncology indications.